Test 1 Prep Flashcards

1
Q

antifebrin

A
  • first synthetic drug for fevers on the market
  • made of acetanilide (chemical from coal-tar waste found to be effective in reducing fevers)
  • lead to synthesis of Aspirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What was the impact of WWI and WWII on pharmacology?

A
  • effects of chemical warfare transformed chemotherapy for blood cancers (ie leukaemia, lymphoma)
  • mass scale production of penicillin and antibiotics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

racemic mixture

A

50/50 mixture of both enantiomers of a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why did thalidomide (medication for treating morning sickness) result in birth defects?

A
  • morning sickness was just the off target effect
  • true target was the protein responsible for proper limb development
  • as a result, the body did not secrete hormones for limb development and did not experience sickness caused by these hormones
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

process of drug discovery

A
  • identify the problem
  • study the physiology
  • select a target and screen a library OR design a compound
  • test in vitro
  • choose lead compound
  • clinical trials
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

order of drug screen assays

A
  • in vitro (artificial)
  • in vitro (cell based)
  • ex vivo (tissue outside body)
  • in vivo
  • clinical trials
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HTS (high throughput screening)

A
  • testing (screening) thousands of molecules with unknown functions to observe biological effect
  • leads to HIT compound (compound with the desired effect)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

no effect dose

A
  • max dose w/o toxic effect

- initial dose for human testing is 1-10% of this dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

minimum lethal dose

A
  • min dose with lethal effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

LD50 (median lethal dose)

A
  • dose that causes 50% of animals to die
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

acute toxicity testing

A
  • short term exposure drugs

- NED and max tolerated dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

chronic toxicity testing

A
  • long term exposure drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

phases of clinical trials

A
  • phase I: healthy volunteers
  • phase II: patients with target disease (75% fail this stage)
  • phase III: best method of administration (~50% pass)
  • phase IV: released to general population
  • phase V: research
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

describe the nitric oxide pathway

A
  • eNOS turns L-arginine into NO
  • NO diffuses across smooth muscle cell membrane and binds to and activates guanylate cyclase
  • guanylate cyclase turns GTP into cGMP which sends the cell signal for muscle relaxation (vasodilation)
  • PDE5 turns cGMP back into GTP, leading to muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

orphan drugs

A

drugs for rare diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why can’t you have grapefruit juice with some medications?

A
  • grapefruit juice increases absorption by inhibiting enzyme that has to do with drug metabolism, leading to overdose
  • can also inhibit drug transporter, leading to too little drug in the body
17
Q

agonists I

A
  • similar to endogenous ligand
  • activates target pathway
  • can be full, inverse (binds to agonist target but opposes activity stimulated by it) or partial
18
Q

agonists II

A
  • do not mimic endogenous ligand

- activates pathway by inhibiting negative regulators

19
Q

antagonists

A
  • prevents the activity of the endogenous ligand
  • inhibits the target pathway
  • competitive inhibitors: bind to same target as endogenous ligand
20
Q

allosteric regulators

A
  • binds to another alternative pocket
  • does not compete with ligand
  • allosteric agonists enhance target activity
  • allosteric antagonists inhibit target activity
21
Q

IC50

A
  • 1/2 maximum inhibitory concentration
22
Q

difference between Ka, Kd and Ki

A

Ka - equilibrium rate of association between drug and target
Kd - equilibrium rate of dissociation
Ki - equilibrium rate of dissociation in the presence of a ligand

23
Q

EC50

A

1/2 max effect (response) concentration

24
Q

schild equation

A

C’/C = 1 + [l}/Ki

  • C’: EC50 in presence of ligand
  • C: EC50 not in presence of ligand
25
Q

types of drug pathways

A
  • intracellular receptors
  • transmembrane enzyme receptors (binding induces enzyme activity
  • cytokine receptor (recruits other enzymes after ligand binds, activating receptor and signal cascade)
  • ligand/voltage gated ion channel (signal transmitted by changes in ion concentration or voltage)
  • G-protein coupled receptor/GPCR: ligand binding initiates 2nd messenger pathway when G protein dissociates from receptor and activates some enzyme